These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18504612)

  • 21. Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study.
    von Moos R; Caspar CB; Thürlimann B; Angst R; Inauen R; Greil R; Bergstrom B; Schmieding K; Pecherstorfer M
    Ann Oncol; 2008 Jul; 19(7):1266-1270. PubMed ID: 18334511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The first reported case of Atypical Femoral Fracture caused by daily ibandronate prescribed for bone metastases in breast cancer.
    Espey R; Grimes S; Heyburn G; Kealey WD
    BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28487299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Managing metastatic bone disease: three case studies.
    Coleman R; Heidenreich A; Bell R
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):83-6. PubMed ID: 15490382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective randomized controlled clinical trial of zoledronic acid for bone metastases.
    Mystakidou K; Katsouda E; Parpa E; Kouskouni E; Chondros C; Tsiatas ML; Galanos A; Vlahos L
    Am J Hosp Palliat Care; 2006; 23(1):41-50. PubMed ID: 16450662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression.
    Binkley N; Silverman SL; Simonelli C; Santiago N; Kohles JD; Dasic G; Sunyecz JA
    Osteoporos Int; 2009 Sep; 20(9):1595-601. PubMed ID: 19145396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.
    Tripathy D; Lichinitzer M; Lazarev A; MacLachlan SA; Apffelstaedt J; Budde M; Bergstrom B;
    Ann Oncol; 2004 May; 15(5):743-50. PubMed ID: 15111341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ibandronate reduces skeletal morbidity in patients with breast cancer.
    Tripathy A D; Diel I; Body JJ
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):64-6. PubMed ID: 15490378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer.
    Hoskin P; Sundar S; Reczko K; Forsyth S; Mithal N; Sizer B; Bloomfield D; Upadhyay S; Wilson P; Kirkwood A; Stratford M; Jitlal M; Hackshaw A
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26242893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease.
    Jagdev SP; Purohit P; Heatley S; Herling C; Coleman RE
    Ann Oncol; 2001 Oct; 12(10):1433-8. PubMed ID: 11762816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis: A Meta-Analysis.
    Hou Y; Gu K; Xu C; Ding H; Liu C; Tuoheti Y
    Medicine (Baltimore); 2015 Jul; 94(26):e1007. PubMed ID: 26131800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
    Clemons M; Dranitsaris G; Ooi W; Cole DE
    Breast Cancer Res Treat; 2008 Mar; 108(1):79-85. PubMed ID: 17473981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
    J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer.
    Body JJ; Diel IJ; Bell R; Pecherstorfer M; Lichinitser MR; Lazarev AF; Tripathy D; Bergström B
    Pain; 2004 Oct; 111(3):306-312. PubMed ID: 15363874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ibandronate in metastatic bone pain.
    Heidenreich A; Ohlmann C; Body JJ
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):67-72. PubMed ID: 15490379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain.
    Altundag K; Dizdar O; Ozsaran Z; Ozkok S; Saip P; Eralp Y; Komurcu S; Kuzhan O; Ozguroglu M; Karahoca M
    Onkologie; 2012; 35(5):254-8. PubMed ID: 22868504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
    Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
    Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
    Himelstein AL; Foster JC; Khatcheressian JL; Roberts JD; Seisler DK; Novotny PJ; Qin R; Go RS; Grubbs SS; O'Connor T; Velasco MR; Weckstein D; O'Mara A; Loprinzi CL; Shapiro CL
    JAMA; 2017 Jan; 317(1):48-58. PubMed ID: 28030702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
    Gralow JR; Barlow WE; Paterson AHG; M'iao JL; Lew DL; Stopeck AT; Hayes DF; Hershman DL; Schubert MM; Clemons M; Van Poznak CH; Dees EC; Ingle JN; Falkson CI; Elias AD; Messino MJ; Margolis JH; Dakhil SR; Chew HK; Dammann KZ; Abrams JS; Livingston RB; Hortobagyi GN
    J Natl Cancer Inst; 2020 Jul; 112(7):698-707. PubMed ID: 31693129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.